From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

enfortumab vedotin   Click here for help

GtoPdb Ligand ID: 10738

Synonyms: ASG-22CE | enfortumab vedotin-ejfv | Padcev®
Approved drug
enfortumab vedotin is an approved drug (FDA (2019), EMA (2022))
Compound class: Antibody
Comment: Enfortumab vedotin is an anti-Nectin 4 monoclonal antibody-drug conjugate [3]. The toxic payload is monomethyl auristatin E (MMAE; PubChem CID 11542188). It exhibits potent efficacy in multiple preclinical cancer models [1].
References
1. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR et al.. (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Cancer Res, 76 (10): 3003-13. [PMID:27013195]
2. Hanna KS. (2020)
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Drugs, 80 (1): 1-7. [PMID:31823332]
3. McGregor BA, Sonpavde G. (2019)
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
Expert Opin Investig Drugs, 28 (10): 821-826. [PMID:31526130]